These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 6364090)

  • 1. A review of the drug events reported by 12,917 patients treated with cephalexin.
    Burt RA
    Postgrad Med J; 1983; 59 Suppl 5():47-53. PubMed ID: 6364090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of cefadroxil and cephalexin in children and adolescents with pyodermas. Cefadroxil Once Daily Pyoderma Study Group.
    Linder CW; Nelson K; Paryani S; Stallworth JR; Blumer JL
    Clin Ther; 1993; 15(1):46-56. PubMed ID: 8458054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of two dosage schedules of cephalexin in dermatologic infections.
    DiMattia AF; Sexton MJ; Smialowicz CR; Knapp WH
    J Fam Pract; 1981 Apr; 12(4):649-52. PubMed ID: 7205167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.
    Giordano PA; Elston D; Akinlade BK; Weber K; Notario GF; Busman TA; Cifaldi M; Nilius AM
    Curr Med Res Opin; 2006 Dec; 22(12):2419-28. PubMed ID: 17257456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of twice daily cephalexin.
    Browning AK
    Pharmatherapeutica; 1981; 2(9):559-64. PubMed ID: 7267673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cephalexin in the treatment of skin and soft-tissue infections.
    Derrick CW; Reilly K
    Postgrad Med J; 1983; 59 Suppl 5():43-6. PubMed ID: 6364089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections.
    Parish LC; Routh HB; Miskin B; Fidelholtz J; Werschler P; Heyd A; Haverstock D; Church D
    Int J Clin Pract; 2000 Oct; 54(8):497-503. PubMed ID: 11198726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds.
    Kraus SJ; Eron LJ; Bottenfield GW; Drehobl MA; Bushnell WD; Cupo MA
    J Fam Pract; 1998 Dec; 47(6):429-33. PubMed ID: 9866667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Represcription of penicillin after allergic-like events.
    Apter AJ; Kinman JL; Bilker WB; Herlim M; Margolis DJ; Lautenbach E; Hennessy S; Strom BL
    J Allergy Clin Immunol; 2004 Apr; 113(4):764-70. PubMed ID: 15100685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral cephalexin for acne vulgaris: clinical experience with 93 patients.
    Fenner JA; Wiss K; Levin NA
    Pediatr Dermatol; 2008; 25(2):179-83. PubMed ID: 18429774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the safety of isepamicin in adults.
    Blum D
    J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility.
    Kearns GL; Wheeler JG; Childress SH; Letzig LG
    J Pediatr; 1994 Nov; 125(5 Pt 1):805-11. PubMed ID: 7965438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy.
    Prescott WA; DePestel DD; Ellis JJ; Regal RE
    Clin Infect Dis; 2004 Apr; 38(8):1102-7. PubMed ID: 15095214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the safety profile of cefixime.
    Wu DH
    Clin Ther; 1993; 15(6):1108-19. PubMed ID: 8111808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug allergy: fact or fiction?
    Bowrey DJ; Morris-Stiff GJ
    Int J Clin Pract; 1998; 52(1):20-1. PubMed ID: 9536562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?
    Claessens AA; Heerdink ER; van Eijk JT; Lamers CB; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2002 Dec; 11(8):703-8. PubMed ID: 12512247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.
    Budnitz DS; Pollock DA; Mendelsohn AB; Weidenbach KN; McDonald AK; Annest JL
    Ann Emerg Med; 2005 Feb; 45(2):197-206. PubMed ID: 15671977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical tolerability profile of alendronate.
    Watts N; Freedholm D; Daifotis A
    Int J Clin Pract Suppl; 1999 Apr; 101():51-61. PubMed ID: 12669741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.